Status:
COMPLETED
A Twelve-Week Study of Varenicline for Safety and Efficacy in Comparison With Placebo for Smoking Cessation
Lead Sponsor:
Pfizer
Conditions:
Smoking Cessation
Eligibility:
All Genders
18-75 years
Phase:
PHASE3
Brief Summary
The primary purpose of this study is to evaluate the safety and efficacy of varenicline given for a twelve week treatment period in comparison with placebo for smoking cessation.
Eligibility Criteria
Inclusion
- Subjects must have smoked an average of at least 10 cigarettes per day during the past year and over the month prior to the screening visit, with no period of abstinence greater than 3 months in the past year.
Exclusion
- Subjects who have used bupropion, Zyban, or Wellbutrin previously.
Key Trial Info
Start Date :
February 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2006
Estimated Enrollment :
250 Patients enrolled
Trial Details
Trial ID
NCT00141167
Start Date
February 1 2005
End Date
January 1 2006
Last Update
September 6 2010
Active Locations (10)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Anyang-si, Gyeonggi-do, South Korea, 431-070
2
Pfizer Investigational Site
Daegu, South Korea, 700-712
3
Pfizer Investigational Site
Seoul, South Korea, 100-032
4
Pfizer Investigational Site
Seoul, South Korea, 110-744